ReviewExpert review of vaccines2015
Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.
Review in Expert review of vaccines, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 52 citations in OpenAlex.
- The expression panel of CXCL9, GBP5, and IFNG is a potential pan-cancer biomarker to predict immunotherapy response.American journal of translational research · 2023Article
- CD8A as a Prognostic and Immunotherapy Predictive Biomarker Can Be Evaluated by MRI Radiomics Features in Bladder Cancer.Cancers · 2022Article
- Vitamin B6 Antidepressant Effects Are Comparable to Common Antidepressant Drugs in Bacillus-Calmette-Guerin Induced Depression Model in Mice.Iranian journal of psychiatry · 2022Article
- Novel molecules as the emerging trends in cancer treatment: an update.Medical oncology (Northwood, London, England) · 2022Review
- Prognostic Signature GXYLT2 Is Correlated with Immune Infiltration in Bladder Cancer.Disease markers · 2022Article
- Copy number variation analysis of mCancer medicine · 2021Article
- Positive QuantiFERON test and the severity of COVID-19 disease: A prospective study.The Indian journal of tuberculosis · 2021Article
- Variances in BCG protection against COVID-19 mortality: A global assessment.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.International immunopharmacology · 2021Review
- Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.Aging and disease · 2021Review
- Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation.Pharmaceutics · 2021Review
- The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview.Frontiers in microbiology · 2021Review
- BCG as a Vector for Novel Recombinant Vaccines against Infectious Diseases and Cancers.Vaccines · 2020Article
- New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?Cellular immunology · 2020Review
- The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.ACS pharmacology & translational science · 2020Review
- Proposing BCG Vaccination forMicroorganisms · 2020Review
- Vaccines Against Tuberculosis: Problems and Prospects (Review).Applied biochemistry and microbiology · 2020Article
- Immunopathogenesis of COVID-19: Summary and Possible Interventions.Frontiers in immunology · 2020Review
- Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.The Journal of pathology · 2019Review
- Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.Medicinal research reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Bacillus Calmette-Guerin (BCG) vaccines are attenuated live strains of Mycobacterium bovis and are among the most widely used vaccines in the world. BCG is proven to be effective in preventing severe infant meningitis and miliary tuberculosis. Intravesical instillation of BCG is also a standard treatment for non-muscle invasive bladder cancer. In the past few decades, recombinant BCG (rBCG) technology had been extensively applied to develop vaccine candidates for a variety of infectious diseases, including bacterial, viral, and parasite infections, and to improve the efficacy of BCG in bladder cancer therapy. This review is intended to show the vast applications of BCG and recombinant BCG (rBCG) in the prevention of infectious diseases and cancer immunotherapy, with a special emphasis on recent approaches and trends on both pre-clinical and clinical levels.
Indexed as
Identifiers
26268434PMC4920355W1843355170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.